Icodextrin Fulfills Unmet Clinical Need of PD Patients: Improved Ultrafiltration

Dialysis and Transplantation

Volumn 32, Issue 11, 2003, Pages 675-684

  Hamburger, Richard J ^a   Kraus, Michael Alan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXTRANEAL; GLUCOSE; ICODEXTRIN; OSMOTIC AGENT;

BLOOD PRESSURE REGULATION; FLUID BALANCE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ULTRAFILTRATION;

EID: 0242710164     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S5-S21.
2. Pecoits-Filho RF, Mujais S, Lindholm B. Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int 2002; 62(Suppl 81):S80-S87.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
4. Lameire N, Van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Perit Dial Int 1997; 17(Suppl 2):S102-S110.
5. Prichard S, Sniderman A, Cianflone K, Marpole D. Cardiovascular disease in peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1):S19-S22.
6. Lameire N, Bernaert P, Lambert MC, Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; 48(Suppl):S31-S38.
7. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
8. Peers E, Gokal R. Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume. Artif Organs 1998; 22:8-12.
9. Mujais S, Vonesh E. Profiling of peritoneal ultrafiltration. Kidney Int 2002; 62(Suppl 81):S17-S22.
10. Mistry CD, Gokal R, Peers E, MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994; 46:496-503.
11. Wolfson M, Piraino B, Hamburger RJ, Mortin AR, for the Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-1065.
12. Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862-871.
13. Posthuma N, Donker AJM, Peers EM, Oe PL, Verbrugh HA. Icodextrin use in CCPD patients during peritonitis: Ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 1998; 13:2341-2344.
14. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000; 15:862-866.
15. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14:2338-2344.
16. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 2003; 63:1556-1563.
17. Stein A, Peers E, Hattersley J, Harris K, Feehally J, Walls J. Clinical experience with icodextrin in continuous ambulatory peritoneal dialysis patients [MIDAS Study Group]. Perit Dial Int 1994; 14(Suppl 2):S51-S54.
18. Peers EM, Scrimgeour AC. Icodextrin can prolong technique survival in CAPD patients with ultrafiltration failure [abstract]. J Am Soc Nephrol 1995; 6:513.
19. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival. Perit Dial Int 1997; 17:84-87.
20. Johnson DW, Vincent K, Blizzard S, Rumpsfeld M, Just P. Cost savings from peritoneal dialysis therapy time extension using icodextrin. Adv Perit Dial 2003; 19:81-85.
21. Bandiani G, Camaiora E, De Lucia ED, Nicolini MA, Perotta U, Zattera T. Use of icodextrin in the treatment of patients with congestive heart failure (CHF) and fluid overload [abstract]. Perit Dial Int 2001; 21(Suppl 2):S105.
22. Dratwa M, Mesquita M, Paciorkowski F, et al. Peritoneal ultrafiltration (UF) with Extraneal® for overhydration due to congestive heart failure (CHF) and nephrotic syndrome [abstract]. Perit Dial Int 2000; 20:121.
23. Hellberg O, Wilstrom G. Continuous ambulatory peritoneal ultrafiltration using icodextrin to treat congestive heart failure resistant to diuretics [abstract]. Perit Dial Int 2001; 21(Suppl 1):S26.
24. Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001; 17:80-84.
25. Bredie SJH, Bosch FH, Demacker PNM, Stalenhoef AFH, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21:275-281.
26. Cooker LA, Holmes CJ, Hoff CM. Biocompatibility of icodextrin, Kidney Int 2002; 62(Suppl 81):S34-S45.
27. Posthuma N, ter Wee PM, Donker AJM, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis [The Dextrin in APD in Amsterdam (DIANA) Group]. Perit Dial Int 2000; 20(Suppl 2):S106-S113.
28. Davies SJ, Brown EA, Riegel W, et al. Influence of glucose exposure and icodextrin use on longitudinal changes in membrane function in anuric APD patients [abstract]. Perit Dial Int 2003; 23(Suppl 1):S17.
29. Araujo MRT, Pecoits-Filho RF, Romao JE Jr, Sabbaga E, Marcondes MM, Abensur H. The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test. Perit Dial Int 2002; 22:229-233.
30. Krediet RT, Ho-dac-Pannekeet MM, Imholz AL, Struijk DG. Icodextrin's effects on peritoneal transport. Perit Dial Int 1997; 17:35-41.
31. Krediet RT, Brown CB, Imholz ALT, Koomen GCM. Protein clearance and icodextrin. Perit Dial Int 1994; 14(Suppl 2):S39-S44.
32. Opatrna S, Opatmy K Jr, Racek J, Sefrna F. Effect of icodextrin-based dialysis solution on peritoneal leptin clearance. Perit Dial Int 2003; 23:89-91.
33. Wolfson M, Ogrinc F, Mujais S. Review of clinical trial experience with icodextrin. Kidney Int 2002; 62(Suppl 81):46-52.
34. EXTRANEAL [package insert]. Deerfield, IL: Baxter Healthcare Corporation, 2002.
35. Data on file, Baxter Healthcare Corporation.
36. Posthuma N, ter Wee PM, Donker AJM, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as day-time dwell. Perit Dial Int 1997; 17:602-607.
37. Gradden C, Livesley P, Ahmad R, Bell GM. Serious neurological complications secondary to hyponatremia in patients using icodextrin in peritoneal dialysis (PD) [abstract]. J Am Soc Nephrol 1999; 10:314A.
38. Woodrow G, Stables G, Oldroyd B, Gibson J, Turney JH, Brownjohn AM. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant 1999; 14:1530-1535.